Detalhe da pesquisa
1.
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
J Clin Oncol
; 21(22): 4105-11, 2003 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14559891
2.
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone.
J Clin Oncol
; 19(6): 1759-67, 2001 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11251007
3.
Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
Eur J Cancer
; 39(10): 1395-401, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12826042
4.
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Eur J Cancer
; 39(8): 1074-80, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12736106
5.
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
Eur J Cancer
; 40(3): 403-10, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-14746859
6.
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Eur J Cancer
; 37(7): 835-42, 2001 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-11313170
7.
Pharmacokinetics of rizatriptan tablets during and between migraine attacks.
Headache
; 39(4): 264-9, 1999 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15613223
8.
Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis.
J Pharm Sci
; 88(5): 568-73, 1999 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-10229651
9.
A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
Indian J Cancer
; 50(4): 285-91, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24369195
10.
Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery.
Br J Anaesth
; 99(2): 202-11, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17540667
11.
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response.
Support Care Cancer
; 14(4): 354-60, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16450086
12.
Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia.
Kidney Int
; 56(5): 1879-85, 1999 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-10571797
13.
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.
N Engl J Med
; 340(3): 190-5, 1999 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-9917226